Bristol-Myers Squibb Company (BMY)

The market's performance in the three months leading up to a presidential election has displayed an uncanny ability to forecast which party will win the White House.

BMY sees reason for optimism over the final half of the year.

Check out the Dow Transports and the Dow Industrials.

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

They buy and buy and buy. The same stocks. Over and over. No end to it.

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

At the end of the day, investors really have only three choices to make when managing an investment portfolio -- buy, hold, or sell.

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Merger activity is the number 1 driver I am watching for biotech growth.

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

These companies all could be strong -- even if the 2019 nCoV fear spreads.

BlackRock's CEO will now make investment decisions based on a company's commitment to environmental sustainability. You can bet the financial world will never be the same again.

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

Let's review the charts.

The Medical Technology Stock Letter's top pick rose 357% in 2019.

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.